Tianjin Tianyao Pharmaceuticals Co Ltd (600488) - Total Liabilities
Based on the latest financial reports, Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has total liabilities worth CN¥1.85 Billion CNY (≈ $270.54 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Tianjin Tianyao Pharmaceuticals Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Tianjin Tianyao Pharmaceuticals Co Ltd - Total Liabilities Trend (1998–2024)
This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 600488 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Tianjin Tianyao Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Tianyao Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dogus Otomotiv Servis ve Ticaret AS
IS:DOAS
|
Turkey | TL58.84 Billion |
|
Cleanaway Co Ltd
TW:8422
|
Taiwan | NT$12.77 Billion |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
Gr. Sarantis S.A.
AT:SAR
|
Greece | €232.08 Million |
|
Ls Cable & System Asia Ltd
KO:229640
|
Korea | ₩282.72 Billion |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
China | CN¥399.59 Million |
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
Germany | €980.61 Million |
|
Groupe Dynamite Inc
TO:GRGD
|
Canada | CA$711.96 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Tianjin Tianyao Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600488 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Tianyao Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Tianyao Pharmaceuticals Co Ltd (1998–2024)
The table below shows the annual total liabilities of Tianjin Tianyao Pharmaceuticals Co Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion ≈ $265.21 Million |
-24.14% |
| 2023-12-31 | CN¥2.39 Billion ≈ $349.61 Million |
-17.53% |
| 2022-12-31 | CN¥2.90 Billion ≈ $423.90 Million |
+14.58% |
| 2021-12-31 | CN¥2.53 Billion ≈ $369.95 Million |
+5.19% |
| 2020-12-31 | CN¥2.40 Billion ≈ $351.70 Million |
+41.78% |
| 2019-12-31 | CN¥1.70 Billion ≈ $248.07 Million |
+11.65% |
| 2018-12-31 | CN¥1.52 Billion ≈ $222.18 Million |
+31.59% |
| 2017-12-31 | CN¥1.15 Billion ≈ $168.83 Million |
+125.69% |
| 2016-12-31 | CN¥511.21 Million ≈ $74.81 Million |
-12.53% |
| 2015-12-31 | CN¥584.42 Million ≈ $85.52 Million |
+16.57% |
| 2014-12-31 | CN¥501.34 Million ≈ $73.36 Million |
-36.19% |
| 2013-12-31 | CN¥785.64 Million ≈ $114.96 Million |
+8.50% |
| 2012-12-31 | CN¥724.13 Million ≈ $105.96 Million |
-0.79% |
| 2011-12-31 | CN¥729.86 Million ≈ $106.80 Million |
-43.34% |
| 2010-12-31 | CN¥1.29 Billion ≈ $188.50 Million |
+20.67% |
| 2009-12-31 | CN¥1.07 Billion ≈ $156.21 Million |
-0.04% |
| 2008-12-31 | CN¥1.07 Billion ≈ $156.27 Million |
+24.96% |
| 2007-12-31 | CN¥854.65 Million ≈ $125.06 Million |
-36.59% |
| 2006-12-31 | CN¥1.35 Billion ≈ $197.24 Million |
+44.40% |
| 2005-12-31 | CN¥933.43 Million ≈ $136.59 Million |
+72.50% |
| 2004-12-31 | CN¥541.10 Million ≈ $79.18 Million |
-19.15% |
| 2003-12-31 | CN¥669.25 Million ≈ $97.93 Million |
+5.48% |
| 2002-12-31 | CN¥634.50 Million ≈ $92.85 Million |
+51.29% |
| 2001-12-31 | CN¥419.39 Million ≈ $61.37 Million |
+44.11% |
| 2000-12-31 | CN¥291.03 Million ≈ $42.59 Million |
+9.99% |
| 1999-12-31 | CN¥264.61 Million ≈ $38.72 Million |
+27.88% |
| 1998-12-31 | CN¥206.93 Million ≈ $30.28 Million |
-- |
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more